Behavioral and Physiological Effects of THC and CBD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-31

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate physiological and behavioral responses to vaporized delta9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) administered via inhalation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessing the Effects of a Cannabidiol Derived From Hemp Supplement in Healthy Adults

NCT05212402

Healthy Safety Issues

COMPLETED NA

Evaluation of Oral THC and CBD in Men and Women

NCT05067387

Drug Abuse Intoxication by Drug Impairment

NOT_YET_RECRUITING PHASE1

Evaluation of Smoked THC and CBD in Men and Women

NCT05037487

Drug Abuse Intoxication by Drug Impairment

RECRUITING PHASE1

The Pharmacodynamics of Cannabinoid-Caffeine Combinations

NCT05478863

Behavioral Pharmacology of Cannabinoids

COMPLETED EARLY_PHASE1

THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy

NCT06859710

Abuse, Drug Pain

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The proposed study will be conducted at the Johns Hopkins Behavioral Pharmacology Research Unit (BPRU). In this between-subjects study, participants will be randomized to complete 1 of 8 possible acute drug administration sessions in which participants will administer THC alone, CBD alone, THC and CBD together, or placebo. Following drug administration, participants will complete a performance session and complete a battery of questionnaires assessing subjective drug effects, mood, affect, and mental state. Vital signs and hormone levels will also be assessed before and after drug administration. The study will help the investigators understand the individual and interactive effects of THC and CBD, the two most common cannabis constituents.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Outcome Assessors

placebo controlled, double-blind

Intervention Type DRUG

Acute exposure to vaporized CBD with THC

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have provided written informed consent
* Be between the ages of 18 and 50
* Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
* Willingness to provide urine sample at the screening visit and again upon admission for the experimental session
* Test negative for recent drug or alcohol use at the screening visit and upon arrival for each experimental session.
* Not be pregnant or nursing (if female). All females must have a negative pregnancy test at the screening visit and at clinic admission.
* BMI 18-36
* Blood pressure at screening visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
* Occasional/Intermittent cannabis users.
* Have not donated blood in the prior 30 days.

Exclusion Criteria

* Recent non-medical use of psychoactive drugs;
* History of or current evidence of significant medical or psychiatric illness
* any condition (as determined by the study physician or investigator) that puts the participant at greater risk.
* Recent use of an over the counter (OTC), systemic or topical drug(s), herbal supplement(s), or vitamin(s) which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.
* Recent use of a prescription medication (with the exception of hormonal birth control prescriptions) which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. This includes any medication metabolized via CYP2D6, CYP2C9, CYP2B10, or which induce/inhibit CYP3A4 enzymes.
* Recent use of hemp seeds or hemp oil.
* Recent use of dronabinol (Marinol).
* History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina).
* Recently enrolled in another clinical trial or have recently received any drug as part of a research study.
* Epilepsy or a history of seizures.
* Individuals who have a recent history of traumatic brain injury diagnosed by CT/MRI and have current sequela from prior brain injury, as determined by the study physician
* Individuals with anemia
* 5th grade reading level or lower.
* Clinically relevant anxiety.
* Individuals who are night shift workers

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes